Genome editing company Precision proposes $100M IPO

March 1, 2019

With plans to bring an allogeneic CAR T immunotherapy into the clinic, Precision BioSciences Inc. (Durham, N.C.) proposed Friday to raise up to $100 million in an IPO on NASDAQ.

With plans to bring an allogeneic CAR T immunotherapy into the clinic, Precision BioSciences Inc. (Durham, N.C.) proposed Friday to raise up to $100 million in an IPO on NASDAQ.

Precision plans to start this half a Phase I/IIa trial of lead program, PBCAR0191, in acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). The allogeneic CAR T cell therapy targeting CD19 has Orphan Drug designation in the U.S. to treat ALL.

The company also has CAR T therapies targeting CD20, BCMA and CLEC12A in preclinical development. Precision plans to submit an IND to FDA for the CD20-targeting therapy in 4Q19, and is aiming to submit INDs for the other two programs next year.

Read full news article here.